Scarica l'app Stockscreener
1.80
4.96%
0.085
Dopo l'orario di chiusura:
1.78
-0.02
-1.11%
Precedente Chiudi:
$1.715
Aprire:
$1.72
Volume 24 ore:
286.70K
Relative Volume:
0.89
Capitalizzazione di mercato:
$95.99M
Reddito:
-
Utile/perdita netta:
$-59.69M
Rapporto P/E:
-1.3139
EPS:
-1.37
Flusso di cassa netto:
$-46.54M
1 W Prestazione:
+0.00%
1M Prestazione:
-3.23%
6M Prestazione:
+29.50%
1 anno Prestazione:
-34.78%
Intervallo 1D:
$1.7095
$1.805
Intervallo di 1 settimana:
$1.68
$1.8556
Portata 52W:
$1.12
$2.93
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Nome
Milestone Pharmaceuticals Inc
Settore
Industria
Telefono
(514) 336-0444
Indirizzo
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Confronta MIST con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.80 | 95.99M | 0 | -59.69M | -46.54M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-22 | Iniziato | Rodman & Renshaw | Buy |
| 2023-06-20 | Downgrade | Jefferies | Buy → Hold |
| 2022-04-22 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2020-07-29 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-07-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-03-25 | Downgrade | Jefferies | Buy → Hold |
| 2020-03-24 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-03-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2019-06-04 | Iniziato | Oppenheimer | Outperform |
| 2019-06-03 | Iniziato | Cowen | Outperform |
| 2019-06-03 | Iniziato | Jefferies | Buy |
| 2019-06-03 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Milestone Pharmaceuticals Inc Borsa (MIST) Ultime notizie
MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development - AccessWire
Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of Cd228 X 4-1Bb Bispecific Molecule (Mabcalin Sgn-Bb228 (Prs-346) - Marketscreener.com
Novartis Ag ADR (NVS-N) QuotePress Release - The Globe and Mail
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement for PLUVICTO™ - Barchart
Jazz Pharmaceuticals Marks International Volunteers Day with Corporate Impact Milestone - StockTitan
Medigene Receives Milestone Payment from Regeneron Pharmaceuticals, Inc. - Marketscreener.com
Sudden Hearing Loss Study Reaches Milestone: AudioCure Pharma Enrolls More Than Half of the Patients in AC102 Study - Yahoo Finance
Milestone Pharmaceuticals to Present at the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook is Bright - MSN
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Rare milestone for Canadian biotech as Zymeworks-developed drug gets FDA approval - The Globe and Mail
FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework - Benzinga
Update on Clinical MilestoneCytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies - Yahoo Finance
Seres Therapeutics Q3 2024 Earnings Preview - MSN
NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaViaReflecting the Company's Focus on Cardiometabolic Diseases - Yahoo Finance
Milestone Pharmaceuticals Inc. (MIST) Quarterly 10-Q Report - Quartz
Milestone Pharmaceuticals: Q3 Earnings Snapshot - Darien Times
Gyre Therapeutics Revenue Falls 20% as Phase 3 Trial Milestone Nears Critical Data | GYRE Stock News - StockTitan
Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update - The Manila Times
Milestone Pharma Trims Losses 38% as CARDAMYST Shows Strong Phase 3 Results in China | MIST Stock News - StockTitan
BridgeBio's Acoramidis Nears FDA Approval; $500M Milestone Payment Awaits | BBIO Stock News - StockTitan
Armata Pharmaceuticals Hits Key Milestone in Bacteriophage Therapy Trial, Eyes 2025 Data | ARMP Stock News - StockTitan
Arcturus Therapeutics Hits $25M Milestone, Narrows Losses Despite Revenue Dip | ARCT Stock News - StockTitan
Royalty Pharma Reports Third Quarter 2024 Results - ForexTV.com
Argenica Therapeutics' Phase 2 stroke drug trial hits major milestone - Proactive Investors USA
Does Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet? - Simply Wall St
Recursion Pharmaceuticals Reports Q3 2024 Earnings and Strategic Milestones - TipRanks
Head to Head Analysis: Milestone Pharmaceuticals (NASDAQ:MIST) & Alkermes (NASDAQ:ALKS) - Defense World
InnoCare Pharma (SEHK:9969) Achieves Key Milestone with ICP-488 Phase II Success in Psoriasis Treatment - Yahoo Finance
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
CNSPCNS Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Creso Pharma Limited Exceeds Milestone of 3 Million Anibidiol® Doses Sold in Europe - Marketscreener.com
Advaxis Announces Receipt of Funding Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies - Marketscreener.com
FDA Approval Of Orlynvah For Urinary Tract Infections Marks Milestone For Iterum, Paves Way For New Strategic Partnerships - Yahoo Finance
MSD acquires cancer therapeutics developer Modifi Biosciences - Pharmaceutical Technology
Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche - BioSpace
Biotech stock tumbles after unexplained 1,446% gain - MSN
Candel therapeutics investor sells $243,834 in stock By Investing.com - Investing.com South Africa
Milestone Pharmaceuticals (NASDAQ:MIST) Earns Buy Rating from HC Wainwright - MarketBeat
Wainwright maintains Buy rating on Milestone Pharma stock By Investing.com - Investing.com UK
Millennium Management LLC Sells 105,682 Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) - Defense World
Individual investors account for 54% of Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) ownership, while institutions account for 46% - Yahoo Finance
IRLAB Receives Milestone Payment of USD 2.5 million in Conjunction with First Dosing in a Phase I Study with IRL757 in Healthy Older Adults - Yahoo Finance
OKUR stock soars to all-time high, reaching $20 milestone - Investing.com
NRx Pharmaceuticals Advances Towards FDA Approval with Key Stability Milestone for NRX-100 - MyChesCo
1 AI Biotech Stock That Just Scored a Major Milestone - TradingView
1 AI Biotech Stock That Just Scored A Major Milestone - Barchart
Antiarrhythmic Drugs Market Size And Share Report, 2030 - Grand View Research
Milestone Pharmaceuticals Inc Azioni (MIST) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):